Representative Frank Pallone (D-NJ) (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)

May 5, 2022 10:43 AM EDTUpdated 01:39 PM

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations

Zachary Brennan

Senior Editor

Newly proposed, must-pass bipartisan legislation that pays the FDA over the next five years for its reviews of new medical products may also include new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival